280 related articles for article (PubMed ID: 27028808)
1. [The Biological Function of SHP2 in Human Disease].
Li SM
Mol Biol (Mosk); 2016; 50(1):27-33. PubMed ID: 27028808
[TBL] [Abstract][Full Text] [Related]
2. The tyrosine phosphatase Shp2 (PTPN11) in cancer.
Chan G; Kalaitzidis D; Neel BG
Cancer Metastasis Rev; 2008 Jun; 27(2):179-92. PubMed ID: 18286234
[TBL] [Abstract][Full Text] [Related]
3. Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.
Huang WQ; Lin Q; Zhuang X; Cai LL; Ruan RS; Lu ZX; Tzeng CM
Curr Cancer Drug Targets; 2014; 14(6):567-88. PubMed ID: 25039348
[TBL] [Abstract][Full Text] [Related]
4. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; Naoki K; Maris JM; Richardson A; Bardelli A; Sugarbaker DJ; Richards WG; Du J; Girard L; Minna JD; Loh ML; Fisher DE; Velculescu VE; Vogelstein B; Meyerson M; Sellers WR; Neel BG
Cancer Res; 2004 Dec; 64(24):8816-20. PubMed ID: 15604238
[TBL] [Abstract][Full Text] [Related]
5. Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects.
Jopling C; van Geemen D; den Hertog J
PLoS Genet; 2007 Dec; 3(12):e225. PubMed ID: 18159945
[TBL] [Abstract][Full Text] [Related]
6. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
Fragale A; Tartaglia M; Wu J; Gelb BD
Hum Mutat; 2004 Mar; 23(3):267-77. PubMed ID: 14974085
[TBL] [Abstract][Full Text] [Related]
7. Noonan and LEOPARD syndrome Shp2 variants induce heart displacement defects in zebrafish.
Bonetti M; Paardekooper Overman J; Tessadori F; Noël E; Bakkers J; den Hertog J
Development; 2014 May; 141(9):1961-70. PubMed ID: 24718990
[TBL] [Abstract][Full Text] [Related]
8. SHP2 sails from physiology to pathology.
Tajan M; de Rocca Serra A; Valet P; Edouard T; Yart A
Eur J Med Genet; 2015 Oct; 58(10):509-25. PubMed ID: 26341048
[TBL] [Abstract][Full Text] [Related]
9. Protein tyrosine phosphatase SHP2/PTPN11 mistargeting as a consequence of SH2-domain point mutations associated with Noonan Syndrome and leukemia.
Müller PJ; Rigbolt KT; Paterok D; Piehler J; Vanselow J; Lasonder E; Andersen JS; Schaper F; Sobota RM
J Proteomics; 2013 Jun; 84():132-47. PubMed ID: 23584145
[TBL] [Abstract][Full Text] [Related]
10. Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.
Noda S; Takahashi A; Hayashi T; Tanuma S; Hatakeyama M
Biochem Biophys Res Commun; 2016 Jan; 469(4):1133-9. PubMed ID: 26742426
[TBL] [Abstract][Full Text] [Related]
11. Phosphatase-independent functions of SHP2 and its regulation by small molecule compounds.
Guo W; Xu Q
J Pharmacol Sci; 2020 Nov; 144(3):139-146. PubMed ID: 32921395
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of targeting SHP2 in human developmental disorders and cancers.
Shen D; Chen W; Zhu J; Wu G; Shen R; Xi M; Sun H
Eur J Med Chem; 2020 Mar; 190():112117. PubMed ID: 32061959
[TBL] [Abstract][Full Text] [Related]
13. Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways.
Kontaridis MI; Yang W; Bence KK; Cullen D; Wang B; Bodyak N; Ke Q; Hinek A; Kang PM; Liao R; Neel BG
Circulation; 2008 Mar; 117(11):1423-35. PubMed ID: 18316486
[TBL] [Abstract][Full Text] [Related]
14. Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner.
Zheng H; Yu WM; Waclaw RR; Kontaridis MI; Neel BG; Qu CK
Sci Signal; 2018 Mar; 11(522):. PubMed ID: 29559584
[TBL] [Abstract][Full Text] [Related]
15. Counteracting effects operating on Src homology 2 domain-containing protein-tyrosine phosphatase 2 (SHP2) function drive selection of the recurrent Y62D and Y63C substitutions in Noonan syndrome.
Martinelli S; Nardozza AP; Delle Vigne S; Sabetta G; Torreri P; Bocchinfuso G; Flex E; Venanzi S; Palleschi A; Gelb BD; Cesareni G; Stella L; Castagnoli L; Tartaglia M
J Biol Chem; 2012 Aug; 287(32):27066-77. PubMed ID: 22711529
[TBL] [Abstract][Full Text] [Related]
16. Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11).
Qiu W; Wang X; Romanov V; Hutchinson A; Lin A; Ruzanov M; Battaile KP; Pai EF; Neel BG; Chirgadze NY
BMC Struct Biol; 2014 Mar; 14():10. PubMed ID: 24628801
[TBL] [Abstract][Full Text] [Related]
17. Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations.
Yu ZH; Xu J; Walls CD; Chen L; Zhang S; Zhang R; Wu L; Wang L; Liu S; Zhang ZY
J Biol Chem; 2013 Apr; 288(15):10472-82. PubMed ID: 23457302
[TBL] [Abstract][Full Text] [Related]
18. New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling.
Schramm C; Edwards MA; Krenz M
J Biol Chem; 2013 Jun; 288(25):18335-44. PubMed ID: 23673659
[TBL] [Abstract][Full Text] [Related]
19. Noonan syndrome, the Ras-MAPK signalling pathway and short stature.
Binder G
Horm Res; 2009 Apr; 71 Suppl 2():64-70. PubMed ID: 19407499
[TBL] [Abstract][Full Text] [Related]
20. PZR coordinates Shp2 Noonan and LEOPARD syndrome signaling in zebrafish and mice.
Paardekooper Overman J; Yi JS; Bonetti M; Soulsby M; Preisinger C; Stokes MP; Hui L; Silva JC; Overvoorde J; Giansanti P; Heck AJ; Kontaridis MI; den Hertog J; Bennett AM
Mol Cell Biol; 2014 Aug; 34(15):2874-89. PubMed ID: 24865967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
